XOMA (Nasdaq:XOMA) really is a remarkable story in many ways. Few companies have survived so long, and raised capital so many times, and done so little with it. While the company has actually approached $100 million in reported sales, and not many biotechs do even that much, the company has never had any real success in the clinic and has basically strung along successive generations of investors on hype and hope. Now that the company is changing up management yet again, investors should be asking themselves if there is really a good reason to stick by a company that has floundered around for more than 20 years to no real purpose.

Investopedia Markets: Explore the best one-stop source for financial news, quotes, and insights.

A Change at the Top
XOMA announced Wednesday that it's CEO Steve Engle was bailing on the company. Engle said, "I am looking forward to applying my expertise building life science companies in the future."

Hmmm, expertise? Engle became XOMA's CEO in August of 2007. In the those four years, XOMA has gone from a market cap north of $350 million to a current market cap of just under $64 million, and the company really is not a great deal closer to having a winning product in its portfolio.

To be fair, though, Engle did oversee a licensing agreement with Servier that brought a $15 million upfront payment to the company (as well as $20 million more in loans and up to almost half a billion in potential milestones) for XOMA 052 - before the drug bombed in a Phase 2 diabetes study. What's more, Engle was in charge of the company when it monetized its royalty interest in CIMZIA and secured a contract from the National Institute of Allergy and Infectious Disease that could be worth $65 million for anti-botulinum products. Part and parcel of running a biotech is keeping money flowing into the enterprise and Engle was successful in that regard.

A Long History Of Disappointment
If or when XOMA 052 fails, it will be just another in a long line of XOMA setbacks. The company tried to be a player in monoclonal antibodies and had little to show for it - the company's attempts in sepsis failed and the psoriasis drug Raptiva was taken off the market by its partner due to exceptionally severe side-effects (including, ironically, sepsis). Along the way have been other failures in indications like cancer, acne and various autoimmune disorders.

What Now?
The trouble for XOMA shareholders today is that the company has little going for it in the clinic. The company thinks that XOMA 052 still has promise as an IL-1 antibody and gamely talks about a late stage clinical program for Behcet's uveitis and future opportunities in cardiovascular disease, gout and rheumatoid arthritis.

In fact, the company has offered up presentations before highlighting a $18 billion opportunity for IL-1 drugs, with about $7 billion of that from diabetes (now basically just theoretical given the failure of XOMA-052 in diabetes studies). And to be fair, XOMA 052 has shown a strong affinity for IL-1 beta and could be delivered in a convenient monthly dosing schedule.

The problem is, though, that there's just not any real evidence yet to support any of this. Regeneron (Nasdaq:REGN) has an approved IL-1 drug on the market (Arcalyst) and some three years after approval it's annualizing at about $20 million in sales. True, Arcalyst has a limited label and is a different drug, but there's no great clamor to use it off-label.

What's more, Servier is not exactly the strongest partner around and would likely struggle to market an equivocal drug effectively. XOMA has talked about targeting the market for myocardial infarction (a market where almost every biotech has failed) - and competing against the likes of Abbott Labs (NYSE:ABT) and Pfizer (NYSE:PFE) in autoimmune conditions like rheumatoid arthritis. That's a lot of ambition for a company with such a modest track record and an unspectacular partner.

The Bottom Line
Biotech companies like Isis (Nasdaq:ISIS), Vical (Nasdaq:VICL), and XOMA show that decades of disappointment and failure aren't the end of the story so long as they can sell a new generation of investors on their "promising blockbuster technology." To be fair, maybe Isis's mipomersen, Vical's Allovectin-7, or XOMA's XOMA 052 will finally be the winning products that propel the companies to the success that investors have been awaiting for decades.

During that same time period, though, investors could have gone with the likes of Cubist (Nasdaq:CBST), Alexion (Nasdaq:ALXN), Gilead (Nasdaq:GILD) or Celgene (Nasdaq:CELG) and had a great deal more to show for it. Every once in a while a biotech will snag victory from the jaws of long-term defeat, but one of the best predictors of the future in biotech is the past, and investors would do well to bring a healthy dose of skepticism with them to whatever XOMA's new management has to stay about the future of its pipeline. (For additional reading, take a look at A Primer On The Biotech Sector.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Stock Analysis

    3 Stocks that Are Top Bets for Retirement

    These three stocks are resilient, fundamentally sound and also pay generous dividends.
  2. Investing News

    Are Stocks Cheap Now? Nope. And Here's Why

    Are stocks cheap right now? Be wary of those who are telling you what you want to hear. Here's why.
  3. Investing News

    4 Value Stocks Worth Your Immediate Attention

    Here are four stocks that offer good value and will likely outperform the majority of stocks throughout the broader market over the next several years.
  4. Investing News

    These 3 High-Quality Stocks Are Dividend Royalty

    Here are three resilient, dividend-paying companies that may mitigate some worry in an uncertain investing environment.
  5. Stock Analysis

    An Auto Stock Alternative to Ford and GM

    If you're not sure where Ford and General Motors are going, you might want to look at this auto investment option instead.
  6. Mutual Funds & ETFs

    The 4 Best Buy-and-Hold ETFs

    Explore detailed analyses of the top buy-and-hold exchange traded funds, and learn about their characteristics, statistics and suitability.
  7. Mutual Funds & ETFs

    What Exactly Are Arbitrage Mutual Funds?

    Learn about arbitrage funds and how this type of investment generates profits by taking advantage of price differentials between the cash and futures markets.
  8. Investing News

    Ferrari’s IPO: Ready to Roll or Poor Timing?

    Will Ferrari's shares move fast off the line only to sputter later?
  9. Stock Analysis

    5 Cheap Dividend Stocks for a Bear Market

    Here are five stocks that pay safe dividends and should be at least somewhat resilient to a bear market.
  10. Investing

    How to Win More by Losing Less in Today’s Markets

    The further you fall, the harder it is to climb back up. It’s a universal truth that is painfully apparent in the investing world.
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!